Shiwen Lin, PhD, CABA Board Chairman. Dr. Lin is currently the Director, Process & Analytical Technology, Agenus Inc., Lexington, MA. With a total 24 years of post-PhD technical and managerial experience in development functions in the biotechnology/pharmaceutical industry, he has diversified expertise in analytical method development for both small molecule and protein drugs, vaccines, formulation development, process development & scale up, validation, and technology transfer; in-depth knowledge of FDA, EMA, USP, EP, ICH regulations and guidelines. He has his PhD in Analytical Chemistry from Northeastern University, MS in Chemistry, from Chinese Academy of Sciences – Dalian Institute of Chemical Physics, and his BS in Chemistry, from Hubei Normal University. His previous employment include Scientist I, Biogen Inc. (now BiogenIdec) Scientist II, Therion Biologics Corp., Sr. Scientist, BD Bioscience, Director of Analytical Development, InfiMed Therapeutics Inc., Manager of Global Quality Analytical Science, Schering – Plough (now Merck), Group Leader, Vertex Pharmaceuticals Inc.